Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

Marjorie G. Zauderer,Peter W. Szlosarek,Sylvestre Le Moulec,Sanjay Popat,Paul Taylor,David Planchard,Arnaud Scherpereel,Thierry Jahan,Marianna Koczywas,Martin Forster,Robert B. Cameron,Tobias Peikert,Evren Kocabas Argon,Neil Michaud,Jay Yang,Vikram Kansra,Dean A. Fennell

Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.

2020

Marjorie G. Zauderer
Peter W. Szlosarek
Sylvestre Le Moulec
Sanjay Popat
Paul Taylor
David Planchard
Arnaud Scherpereel
Thierry Jahan
Marianna Koczywas
Martin Forster
Robert B. Cameron
Tobias Peikert
Evren Kocabas Argon
Neil Michaud
Jay Yang
Vikram Kansra
Dean A. Fennell

9058Background: Breast cancer gene 1 (BRCA1)-associated protein 1 (BAP1), a nuclear deubiquitinase, is commonly inactivated in malignant mesothelioma. Preclinical data showed that BAP1 inactivation...

Keywords:

Mesothelioma
Tazemetostat
in patient
Refractory
Pathology
Cancer research
Medicine
EZH2
Gene
BAP1
Breast cancer
Deubiquitinating enzyme

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations